5-FUOncology News Saladax Biomedical Welcomes New Guidelines from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) for 5-Fluorouracil Therapy Bethlehem, PA – September 19, 2018 – Saladax Biomedical Inc., a diagnostics company providing kits…John BuckleySeptember 19, 2018
Oncology NewsPaclitaxel Saladax is Awarded “Best Poster Presentation” for Study on Individualized Dosing of Paclitaxel Saladax Biomedical, Inc., recently presented a study on the value of adjusting paclitaxel doses. The…John BuckleyOctober 14, 2017
Corporate News Salvatore J. Salamone, Ph.D., Founder and CEO of Saladax Biomedical, Inc. Inducted into the New Jersey Inventors Hall of Fame Saladax Biomedical, Inc., the leader in developing oncology diagnostics that increase the impact of personalized…John BuckleyOctober 28, 2016
Oncology NewsPaclitaxel Study Shows That Therapeutic Drug Monitoring Can Reduce Paclitaxel-Associated Neuropathy Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic tests, today announced…John BuckleyOctober 19, 2016
Oncology NewsPaclitaxel Saladax Biomedical, Inc. Announces Presentation of CEPAC-TDM Study of Paclitaxel in Non-Small Cell Lung Cancer at 2015 ASCO Meeting Large Study Confirms the Benefit to Patients of Advanced Dosing Method for Saladax Biomedical, Inc.…John BuckleyJune 9, 2015
5-FU Saladax Biomedical, Inc. Announces the Presentation of the CESAR Study Results for Pharmacokinetically-Guided Dosing of 5-Fluorouracil in Colorectal Cancer at 2015 ASCO Meeting Advantages of a Practical Approach to Personalized Dosing of 5-FU Demonstrated Saladax Biomedical, Inc. recently…John BuckleyJune 8, 2015